Evidence map›Paper›PMID 41342194›Full record

ReviewEuropean heart journal2026

Cardiovascular disease in women: traditional and sex-specific risk factors.

Yolande Appelman, Martha Gulati, Jeanine E Roeters van Lennep, Leslee J Shaw, C Noel Bairey Merz

Abstract readReview
In one paragraph

Review in European heart journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Gaps and disparities in Lp(a) testing before universal screening: A 10-year analysis.International journal of cardiology. Cardiovascular risk and prevention · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yolande AppelmanDepartment of Cardiology, Amsterdam University Medical Centers, Amsterdam Cardiovascular Sciences, Amsterdam, Netherlands.ORCID 0000-0001-5241-7105
Martha GulatiBarbra Streisand Women's Heart Center, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.ORCID 0000-0003-0735-9756
Jeanine E Roeters van LennepDepartment of Internal Medicine, Erasmus MC Cardiovascular Institute, Erasmus MC University Medical Center, Rotterdam, Netherlands.ORCID 0000-0001-6870-9962
Leslee J ShawDepartment of Medicine (Cardiology), Blavatnik Family Women's Health Research Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0003-1268-1491
C Noel Bairey MerzBarbra Streisand Women's Heart Center, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.ORCID 0000-0002-9933-5155

Funding

REVISED CAROL ACT IIU01HL088942 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GELIJNS, ANNE CHRISTINE, MOSKOWITZ, ALAN J · 2007 to 2025
$122.6M
The Microvascular Aging and Eicosanoids - Women's Evaluation of Systemic Aging Tenacity (MAE-WEST) ("You are never too old to become younger!") Specialized Center for Research Excellence (SCORE)U54AG065141 · NIA · CEDARS-SINAI MEDICAL CENTER · PI SHYY, JOHN YJ · 2020 to 2024
$8.7M
Mechanistic registry to study whether infection with Corona Virus Disease 2019 (COVID-19) alters atherosclerotic plaque progressionR01HL159433 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI NARULA, JAGAT, SHAW, LESLEE J · 2021 to 2024
$5.2M
Women's Ischemia Syndrome Evaluation (WISE) - Mechanisms of Coronary Microvascular Dysfunction Leading to Pre-Heart Failure with Preserved Ejection Fraction (HFpEF)R01HL146158 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI BAIREY MERZ, CATHLEEN NOEL · 2019 to 2023
$3.7M
Whole-Heart Myocardial Blood Flow Quantification Using MRIR01HL124649 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI LI, DEBIAO · 2015 to 2018
$3.3M
Myocardial Steatosis in Women with Coronary Microvascular Dysfunction: Defining the Pathway to Heart Failure with Preserved Ejection Fraction (HFpEF)R01HL153500 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI WEI, JANET · 2021 to 2025
$3.2M
Magnetic Resonance Imaging for Global Atherosclerosis Risk AssessmentK23HL125941 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI WEI, JANET · 2016 to 2020
$985k
Barbra Streisand Women's Cardiovascular Research and Education ProgramBlavatnik Family FoundationErika Glazer Women's Heart Health ProjectGilinski FamilyHelen Gurley Brown FoundationLinda Joy Pollin Women's Heart Health ProgramNHLBI NIH HHS K23 HL125941NHLBI NIH HHS R01 HL124649NHLBI NIH HHS R01 HL146158NHLBI NIH HHS R01 HL153500NHLBI NIH HHS R01 HL159433NIA NIH HHS U54 AG065141NIH HHS K23HL125941NIH HHS R01HL124649NIH HHS R01HL146158NIH HHS R01HL153500NIH HHS U54AG065141NIH-NHLBI R01HL159433NIH-NHLBI U01HL088942
6 · The paper itself

Abstract

Cardiovascular disease (CVD) accounts for more deaths in women than breast cancer, lung cancer and chronic lung disease combined, with a comparable mortality to that of men. Many women and physicians do not identify CVD as a major morbidity and mortality in women, resulting in significant delays in diagnosis and treatment. While advances have been made in the diagnosis, treatment and outcomes of CVD in women, there often remains insufficient evidence to guide effective, lifesaving care of women. This review of sex-specific and traditional CVD risk and risk-enhancing factors in women identifies areas of knowledge gaps to consider for investigation. A focus on the coronary vasculature reveals physiological differences of clinical relevance which can be interrogated. Inspection of and addressing disadvantage and gender bias in both the medical and lay communities should continue to be addressed. As CVD results from traditional risk factors and emerging risk-enhancing factors, a focus on the detection of preclinical cardiovascular disease may be of particular importance for women. Unique risk markers originate early in pre-menopausal women, as this is considered a healthy period of life. Awareness and implementation of the existing knowledge of sex-specific risk factors and sex-specific thresholds to educate women and physicians are needed. The anticipated life course of women supports a broadening focus on CVD toward that of lifelong care and emphasize key transitional stages for women-early risk factor onset, pregnancy, menopausal transition, and so on. This review is a call to action to re-envision a health system approach for lifespan prevention, detection, and treatment pathways to reduce CVD risk in women.

Indexed as

Cardiovascular DiseasesFemaleHeart Disease Risk FactorsHumansPregnancyRisk FactorsSex FactorsWomen's HealthHeart diseaseRisk factorsSexWomen

Identifiers

PMID41342194
PMCPMC13247190

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.